Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 6

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
     5,848 
  
    Accretion of debt discount 
     -  
     73 
  
    Gain on settlement of accounts payable 
     (626) 
     - 
  
    Depreciation expense 
     28  
     - 
  
    Impairment of acquired in-process research and development intangible assets 
     16,514  
     - 
  
    Changes in operating assets and liabilities: 

    Research and development tax credit receivable 
     (523) 
     796 
  
    Other tax receivable 
     (532) 
     226 
  
    Prepaid expenses 
     (141) 
     646 
  
    Prepaid expenses – related party 
     -  
     127 
  
    Other assets 
     (667) 
     49 
  
    Accounts payable and accrued liabilities 
     962  
     2,689 
  
    Accounts payable and accrued liabilities – related parties 
     -  
     20 
  
    Deferred liabilities 
     (517) 
     60 
  
    Operating lease liabilities 
     (61) 
     (18)
  
    Net cash used in operating activities 
     (19,638) 
     (22,348)

    CASH FLOWS FROM INVESTING ACTIVITIES 

    Purchase of equipment 
     (899) 
     - 
  
    Net cash used in investing activities 
     (899) 
     - 

    CASH FLOWS FROM FINANCING ACTIVITIES: 

    Net proceeds from sale of common stock and warrants 
     27,544  
     27,789 
  
    Exercise of warrants for cash 
     1  
     - 
  
    Repayments of debt 
     -  
     (7,500)
  
    Net cash provided by financing activities 
     27,545  
     20,289 

    Impact on cash from foreign currency translation 
     (196) 
     (237)

    NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 
     6,812  
     (2,296)
  
    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 
     20,922  
     35,848